| Metric | Value (₹ Cr) | vs Q2 FY25 |
|---|---|---|
| Revenue | 8.0K | 2.3% |
| Total Income | 8.1K | 2.6% |
| Expenditure | 6.9K | 3.2% |
| PBT | 1.2K | 0.7% |
| Net Profit | 845.57 | 3.5% |
| OPM | 6.32% | 1.07pp |
| NPM | 10.37% | 0.07pp |
| EPS | 14.56 | 4.0% |
Aurobindo Pharma Reports 8.5% YoY Increase in Q3FY25 Revenue
07 Feb 2025 · 7 Feb 2025, 01:45 am
Summary
Aurobindo Pharma Limited has announced its consolidated financial results for the third quarter ended December 31, 2024. The company reported a 8.5% YoY increase in revenue from operations, reaching INR 7,979 Cr. The US formulations revenue decreased by 2.3% YoY to INR 3,671 Cr, while Europe formulations revenue increased by 22.7% YoY to INR 2,121 Cr. The net profit for the period stood at INR 846 Cr.
Key Highlights
- 1
Revenue from Operations increased by 8.5% YoY to INR 7,979 Cr
- 2
US formulations revenue decreased by 2.3% YoY to INR 3,671 Cr
- 3
Europe formulations revenue increased by 22.7% YoY to INR 2,121 Cr
- 4
Received final approval for 8 ANDAs from the USFDA
- 5
Net Profit for the period stood at INR 846 Cr
Management Comments
Mr. K. Nithyananda Reddy
We are pleased to report our highest-ever quarterly revenue, driven by volume growth from our diverse and expanding product portfolio coupled with new launches. This performance highlights our resilience. Looking ahead, we are enhancing our manufacturing capabilities and ramping up our specialty and injectable business. With these initiatives, we expect notable profitability improvements and are well-positioned to sustain growth and meet our objectives for the year.
Informational and educational content only. Not investment advice.